Literature DB >> 19621686

A prospective comparison of transthoracic and transhiatal resection for esophageal carcinoma in Asians.

Shah-Hwa Chou1, Hung-Yi Chuang, Meei-Feng Huang, Chia-Hua Lee, Harvey Man-Pun Yau.   

Abstract

BACKGROUND/AIMS: Transthoracic and transhiatal esophagectomy are two common procedures for esophageal cancer resection. Prospective studies comparing the two methods in Asian people are few. In addition, the data comparing their effects on the quality of life are lacking.
METHODOLOGY: A prospective randomized study was conducted from January 2003. Patients of resectable esophageal cancer of comparable stage were allocated to undergo the transthoracic or transhiatal procedure in turn. They were all reconstructed with stomach interposition through the retrosternal route. Discharged patients were followed-up in the outpatient clinic. They were questioned on the topics of (i) severity of pain, (ii) ease of swallowing, (iii) satisfaction of daily activities, (iv) dependence on medications, (v) working ability, (vi) fatigue, (vii) appetite, (viii) sociality, (ix) happiness and (x) self respect, in the third, sixth and twelfth month. Also the demographic data, operative results and survival were recorded.
RESULTS: Up to December 2006, eighty-seven patients of stage II and III, including 71 patients of middle third lesions and 16 lower third lesions were enrolled. The operation time was significantly longer, and the leakage rate was higher in the transthoracic group (Student's t-test and Fischer's exact test, respectively). However, intraoperative blood loss and postoperative hospital stay were not significantly different (Student t-test). Also, the Kaplan-Meier survival curves of these two groups were not significantly different by log-rank test (p=0.286). The score on the quality of life of transhiatal patients was significantly higher than that of transthoracic patients in the third, sixth and twelfth month.
CONCLUSIONS: Transhiatal esophagectomy is a safe and fast procedure. The survival was similar to that of transthoracic approach. Its leakage rate was lower and quality of life was better.

Entities:  

Mesh:

Year:  2009        PMID: 19621686

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  6 in total

1.  Comparison of the clinicopathological characteristics and the survival outcomes between the Siewert type II/III adenocarcinomas.

Authors:  Wei-Han Zhang; Xin-Zu Chen; Kai Liu; Kumar Anil; Kun Yang; Jia-Ping Chen; Zong-Guang Zhou; Jian-Kun Hu
Journal:  Med Oncol       Date:  2014-07-15       Impact factor: 3.064

2.  The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection.

Authors:  Harry H Yoon; Maliha Khan; Qian Shi; Stephen D Cassivi; Tsung-Teh Wu; J Fernando Quevedo; Patrick A Burch; Frank A Sinicrope; Robert B Diasio
Journal:  Mayo Clin Proc       Date:  2010-12       Impact factor: 7.616

Review 3.  Transthoracic vs transhiatal surgery for cancer of the esophagogastric junction: a meta-analysis.

Authors:  Ming-Tian Wei; Yuan-Chuan Zhang; Xiang-Bing Deng; Ting-Han Yang; Ya-Zhou He; Zi-Qiang Wang
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

4.  Transthoracic versus abdominal-transhiatal resection for treating Siewert type II/III adenocarcinoma of the esophagogastric junction: a meta-analysis.

Authors:  Zhi Zheng; Jun Cai; Jie Yin; Jun Zhang; Zhong-Tao Zhang; Kang-Li Wang
Journal:  Int J Clin Exp Med       Date:  2015-10-15

5.  Extended lymphadenectomy in esophageal cancer is debatable.

Authors:  Fernando A M Herbella; Rafael M Laurino Neto; Marco E Allaix; Marco G Patti
Journal:  World J Surg       Date:  2013-08       Impact factor: 3.352

6.  Transthoracic resection versus non-transthoracic resection for gastroesophageal junction cancer: a meta-analysis.

Authors:  Kun Yang; Hai-Ning Chen; Xin-Zu Chen; Qing-Chun Lu; Lin Pan; Jie Liu; Bin Dai; Bo Zhang; Zhi-Xin Chen; Jia-Ping Chen; Jian-Kun Hu
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.